ACC 2022: An Embarrassment of Riches - Updated Guideline Recommendat…

ACC 2022 Conference Coverage

P. Heidenreich

ACC 2023: SGLT2i Use - Dos and Don'ts

ACC 2023 Conference Coverage

A. Armbruster

Which Diuretic(s) Are Best in HF? Update Based on Recent Clinical Tr…

MUSC Cardiology

R. Mentz

AHA 2022: Torsemide Comparison With Furosemide for Management of Hea…

AHA 2022 Conference Coverage

R. Mentz

2021 ADA Highlights: Heart Failure With Reduced Ejection Fraction - …

Michelle Kittleson

Management of Heart Failure

Obafemi Awolowo University

O. A. Akinyele

HFpEF or Amyloidosis? The Right Therapies for Right Patients

Scripps Health

M. Kittleson

TACT2 – Does Chelation Reduce Events in Diabetic Post-MI Patients?

Canadian Collaborative Research Network

N. Singh

Use of MCS in Management of Acute Post-MI VSD

Houston Shock Symposium

D. Ramini

Weight Loss as Treatment for HFpEF: An Update on Drugs and Procedures

MUSC Cardiology

S. Litwin

Hot Topics in Heart Failure ACC.22

ACC 2022 Conference Coverage

N. Ibrahim

Heart Failure Case Presentations

San Diego Heart Failure Symposium for Primary Care and Internal Medicine Physicians

B. Greenberg, G. Fonarow, N. Wettersten, M. Rosa Costanzo

Managing Iron Deficiency in Heart Failure: Recognizing the Need for …

Craig Beavers

ACC 2024 Insights: Stop the Meds! Treat the Comorbidities for Optima…

ACC 2024 Insights

K. Williams

Amyloidosis Types and Pathophysiology

Houston Methodist

B. Trachtenberg

ECMO for Refractory Cardiac Arrest: Mobile MN Community Efforts and …

University of Minnesota

D. Yannopoulos

Cardiac Amyloidosis: A New Era of Diagnostics and Therapeutics

UCLA Health

D. Vucicevic

Cardiogenic Shock: Should IABP or PVADs Be Used in Cardiogenic Shock?

American Heart & Vascular Institute

M. Ansari

Digoxin Update 2023: Are the Current Digoxin Monitoring Guidelines H…

Mary E. Money

Aspirin for the Primary Prevention of Cardiovascular Disease: What C…

Houston Methodist DeBakey Heart and Vascular Center

M. Miedema